Moreover, early‐stage (stages I and II together) and late‐stage (stages III and IV together) patients with high DUXAP9‐206 level had shorter survival times than those with low DUXAP9‐206 expression implying that DUXAP9‐206 level might be indicative of the prognosis of NSCLC patients at various clinical stages. This evidence concerns the gene DUXAP9 and non-small cell lung carcinoma.